Shanghai S.E.
06:00:00 2024-05-27 pm EDT
5-day change
1st Jan Change
56.63
CNY
-0.65%
-2.04%
-17.45%
Hangzhou Alltest Biotech Co., Ltd. agreed to acquire an unknown stake in Hangzhou Weisibo Medical Technology Co., Ltd.
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) agreed to acquire an unknown stake in Hangzhou Weisibo Medical Technology Co., Ltd. on October 18, 2023.
China, HK stocks rise, led by property shares
Apr. 29
RE
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 26
CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.
Feb. 23
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 23
CI
Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback announced on August 17, 2023, has closed with 1,030,000 shares, representing 1.32% for CNY 59.58 million.
Feb. 22
CI
Hangzhou Alltest Biotech Co., Ltd. agreed to acquire an unknown stake in Hangzhou Weisibo Medical Technology Co., Ltd.
Jan. 05
CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.
Jan. 02
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.
23-10-10
CI
Hangzhou Alltest Biotech Co., Ltd.(XSSC:688606) added to S&P Global BMI Index
23-09-18
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-28
CI
Hangzhou Alltest Biotech Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.
23-08-16
CI
Hangzhou Alltest Biotech Co., Ltd. authorizes a Buyback Plan.
23-08-15
CI
Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback announced on July 22, 2022, has expired.
23-07-20
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-27
CI
Hangzhou Tongzhou Biotechnology Co., Ltd. announced that it expects to receive CNY 19 million in funding from Hangzhou Alltest Biotech Co., Ltd.
23-01-08
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-28
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-25
CI
Atomo Diagnostics Limited Signs Agreement with Hangzhou Alltest Biotech Co., Ltd, for Supply of A Covid-19 1 Rapid Antigen Self-Test in the Australian and New Zealand Markets
22-08-22
CI
Hangzhou Alltest Biotech Co., Ltd. announces an Equity Buyback for CNY 115.5 million worth of its shares.
22-07-22
CI
Hangzhou Alltest Biotech Co., Ltd. authorizes a Buyback Plan.
22-07-21
CI
Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-27
CI
Hangzhou Alltest Biotech Co., Ltd.(SHSE:688606) added to Shanghai Stock Exchange Composite Index
22-03-25
CI
Hangzhou Alltest Biotech Co., Ltd.(SHSE:688606) added to Shanghai Stock Exchange A Share Index
22-03-24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Companyâs main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, womenâs health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.
More about the company
1st Jan change
Capi.
-17.45% 610M -6.41% 12.2B -4.07% 8.22B +5.77% 5.72B +28.13% 5.42B -59.44% 2.7B +8.04% 2.63B -6.47% 2.38B +21.84% 2.1B -8.15% 1.81B
Diagnostic & Testing Substances
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HANGZHOU ALLTEST BIOTECH CO., LTD. 
